0000899243-22-029564.txt : 20220823 0000899243-22-029564.hdr.sgml : 20220823 20220823201916 ACCESSION NUMBER: 0000899243-22-029564 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220819 FILED AS OF DATE: 20220823 DATE AS OF CHANGE: 20220823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Huang James CENTRAL INDEX KEY: 0001573160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-20713 FILM NUMBER: 221188639 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DRIVE STREET 2: SUITE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-19 0 0000895051 CASI Pharmaceuticals, Inc. CASI 0001573160 Huang James C/O CASI PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DR. SUITE 300 ROCKVILLE MD 20850 1 0 0 0 Common Stock 2022-08-19 4 P 0 171116 3.2694 A 171116 I See Footnote Common Stock 2022-08-22 4 P 0 23105 3.4641 A 194221 I See Footnote Common Stock 2022-08-23 4 P 0 40000 3.4998 A 234221 I See Footnote Common Stock 191 D The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ James Huang 2022-08-23